Browsing by Keyword "Endocrinology"
Now showing 1 - 4 of 4
Results Per Page
Sort Options
Item Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: Additive effects of combination treatment on lipid regulation(1999) Zambón, Daniel; Ros, Emilio; Rodriguez-Villar, Camino; Laguna, Juan Carlos; Vázquez, Manuel; Sanllehy, Carolina; Casais, Elena; Sol, Josep M.; Hernández, Gonzalo; Centros PRE-FUSION TECNALIA - (FORMER)The most appropriate therapy for combined hyperlipidemia remains to be determined. We compared the lipid-regulating effects of gemfibrozil and lovastatin in 30 patients with familial combined hyperlipidemia (FCHL) in a randomized, double-blind, placebo-controlled crossover study including 8- week courses of one drug followed by a washout period and a crossover phase to the alternate drug. After completion of the trial, open-label combination therapy was given for up to 12 months. Lovastatin was more efficacious than gemfibrozil in the reduction of total cholesterol (23% v 9%, P < .001) and low-density lipoprotein (LDL) cholesterol (28% v 2%, P < .001), whereas gemfibrozil surpassed lovastatin in the reduction of triglycerides (48% v 0%, P < .001) and very-low-density lipoprotein (VLDL) cholesterol (50% v 19%, P = .005) and the increase of high-density lipoprotein (HDL) cholesterol (18% v 4%, P = .005), Lovastatin caused a greater decline in total apolipoprotein B (apo B) and LDL apo B than gemfibrozil, whereas VLDL apo B decreased only after gemfibrozil therapy. Drug-induced changes in lipoprotein composition indicated that gemfibrozil reduced both the number and size of VLDL particles and lovastatin decreased the number of LDL particles. Combined treatment was safe and had additive effects on lipids, causing significant (P < .001) reductions in total cholesterol (32%), triglycerides (51%), LDL cholesterol (34%), and apo B (26%) and an increase in HDL cholesterol (19%). Target LDL cholesterol levels were achieved only in 11% of patients given gemfibrozil alone and triglycerides decreased to target levels in 22% after lovastatin alone, whereas combined therapy normalized both lipid fractions in 96% of patients. Thus, in FCHL gemfibrozil has no effect on LDL cholesterol levels but favorably influences the putative atherogenic alterations of lipoprotein composition that are related to hypertriglyceridemia. Conversely, lovastatin markedly decreases LDL cholesterol but has little effect on triglyceride- rich lipoproteins. Combination treatment safely corrects all of the lipid abnormalities in most patients.Item Role of baseline leptin and ghrelin levels on body weight and fat mass changes after an energy-restricted diet intervention in obese women: Effects on energy metabolism(2011-06) Labayen, Idoia; Ortega, Francisco B.; Ruiz, Jonatan R.; Lasa, Arrate; Simón, Edurne; Margareto, Javier; GenéticaContext: Hormones related to energy balance control may play an important role on weight loss resistance after low-caloric diet (LCD) intervention. Objective: To investigate the predictive value of baseline leptin and ghrelin on body fat mass (FM) loss after 12 wk of LCD intervention and to study whether these associations could be related to changes in resting metabolic rate (RMR). Design: The study comprised a total of 78 obese women (age 36.7 ± 7 yr). We measured, before and after the LCD intervention, FM (dual-energy x-ray absorptiometry) and RMR (kilojoules per kilogram body weight per day, indirect calorimetry). We also analyzed fasting serum leptin and ghrelin, and leptin to ghrelin ratio was calculated. Main Outcome Measures: FM and RMR changes (data at baseline - data after the intervention) were assessed. Results: Baseline serum leptin (r = -0.301; age- and baseline FM-adjusted P = 0.009) and ghrelin (r = 0.314, adjusted P = 0.014) levels as well as leptin to ghrelin levels (r = -0.331; adjusted P = 0.009) were significantly correlated with FM changes. Leptin to ghrelin ratio was significantly correlated with RMR at baseline and after the LCD (both P < 0.010). Baseline leptin to ghrelin ratio significantly predicted changes in RMR after the LCD (r = 0.298; P = 0.019) regardless of age, baseline RMR, and total body weight (r = 0.307; P = 0.016) or FM loss (r = 0.312; P = 0.015). Conclusions: Obese women with higher leptin and lower ghrelin levels at baseline seem to be more resistant to FM loss. The leptin to ghrelin ratio could be proposed as a biomarker for predicting metabolic adaptations to energy restriction treatment and, if confirmed in future studies, as a predictor of treatment success/failure.Item Role of baseline leptin and ghrelin levels on body weight and fat mass changes after an energy-restricted diet intervention in obese women: Effects on energy metabolism (Journal of Clinical Endocrinology and Metabolism (2011) 96, (E996-E1000))(2012-04) Labayen, Idoia; Ortega, Francisco B.; Ruiz, Jonatan R.; Lasa, Arrate; Simón, Edurne; Margareto, Javier; GenéticaItem Role of Β 2-adrenergic receptor polymorphisms on body weight and body composition response to energy restriction in obese women: Preliminary results(2011-01) Ruiz, Jonatan R.; Larrarte, Eider; Margareto, Javier; Ares, Raquel; Labayen, Idoia; Generales; Genética; Tecnalia Research & InnovationWe investigated the role of common Β2-adrenergic receptor (ADRB2) rs1042714 (Gln27Glu) and rs1042713 (Arg16Gly) polymorphisms on body weight and body composition response to 12-week energy-restricted diet in women. The study comprised 78 Spanish obese (BMI: 34.0±2.8kg/m2) women (age: 36.7±7 years). We measured (before and after the dietary intervention) weight and height, and BMI calculated. Moreover, body fat mass and lean mass (LM) were measured by dual energy X-ray absorptiometry. We observed an interaction effect between the Gln27Glu polymorphism and diet-induced changes on body weight (P = 0.006), BMI (P = 0.004), and LM (P = 0.001). Women carrying the Glu allele had a greater reduction in body weight than non-Glu allele carriers (9.5±2.9 vs. 7.0±3.5%, respectively, P = 0.002). Moreover, women with the Glu allele lost more LM than the Gln27Gln group (5.9±2.7 vs. 4.0±2.7%, respectively, P = 0.001). We did not find any significant interaction effect between the Arg16Gly polymorphism and diet-induced changes on the outcome variables (all P 0.1). The results suggest that the ADRB2 Gln27Glu polymorphism has a modulating effect on diet-induced changes on body weight and body composition, and should be considered in future obesity treatments. These findings should be taken as preliminary and be replicated in further energy restriction studies with larger sample sizes.